Jazz Poised To Hold Onto Strong Sleep Disorder Position

Jazz detailed Phase III data on a next-generation narcolepsy drug that could extend the life of its successful Xyrem franchise. The launch of Sunosi also is underway.  

More from Neurological

More from Therapy Areas